Early life stress in depressive patients: HPA axis response to GR and MR agonist

Frontiers in Psychiatry

Volumn 5, Issue JAN, 2014, Pages

  Baes, Cristiane von Werne ^a   Martins, Camila Maria Severi ^a   de Carvalho Tofoli, Sandra Márcia ^a   Juruena, Mário Francisco ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Cortisol; Depression; Early life stress; Glucocorticoid receptors; Hypothalamic pituitary adrenal; Mineralocorticoid receptors

Indexed keywords

EID: 84893533665     PISSN: None     EISSN: 16640640     Source Type: Journal    
DOI: 10.3389/fpsyt.2014.00002     Document Type: Article

References (98)

1. Kendler KS, Sheth K, Gardner CO, Prescott CA. Childhood parental loss and risk for first-onset of major depression and alcohol dependence: the time-decay of risk and sex differences. Psychol Med (2002) 32:1187-94. doi: 10.1017/S0033291702006219.
2. Heim C, Newport J, Heit S, Graham YP, Wilcox M, Bonsall R, et al. Pituitary-adrenal and autonomic responses to stress in women after sexual and physical abuse in childhood. JAMA (2000) 284:592-7. doi:10.1001/jama.284.5.592.
3. Fergusson DM, Swain-Campbell NR, Horwood LJ. Does sexual violence contribute to elevated rates of anxiety and depression in females? Psychol Med (2002) 32:991-6. doi:10.1017/S0033291702005986.
4. Cohen P, Brown J, Smailes E. Child abuse and neglect and the development of mental disorders in the general population. Dev Psychopathol (2001) 13:981-99. doi:10.1017/S0954579401004126.
5. Martins CMS, Tofoli SMC, Baes CVW, Juruena MF. Analysis of the occurrence of early life stress in adult psychiatric patients: a systematic review. Psychol Neurosci (2011) 4:219-27. doi:10.3922/j.psns.2011.2.007.
6. Nemeroff CB, Heim CM, Thase ME, Klein DN, Rush AJ, Schatzberg AF, et al. Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. Proc Natl Acad Sci U S A (2003) 100:14293-6. doi:10.1073/pnas.2336126100.
7. Miniati M, Rucci P, Benvenuti A, Frank E, Buttenfield J, Giorgi G, et al. Clinical characteristics and treatment outcome of depression in patients with and without a history of emotional and physical abuse. J Psychiatr Res (2010) 44:302-9. doi:10.1016/j.jpsychires.2009.09.008.
8. Heim C, Mletzko T, Purselle D, Musselman DL, Nemeroff CB. The dexamethasone/corticotropin-releasing factor test in men with major depression: role of childhood trauma. Biol Psychiatry (2008) 63:398-405. doi:10.1016/j.biopsych.2007.07.002.
9. Tofoli SMC, Baes CVW, Martins CMS, Juruena M. Early life stress, HPA axis, and depression. Psychol Neurosci (2011) 4:229-34. doi:10.3922/j.psns.2011.2.008.
10. Parker KJ, Schatzberg AF, Lyons DM. Neuroendocrine aspects of hypercortisolism in major depression. Horm Behav (2003) 43:60-6. doi:10.1016/S0018-506X(02)00016-8.
11. Juruena MF, Cleare AJ, Pariante CM. The hypothalamic pituitary adrenal axis, glucocorticoid receptor function and relevance to depression. Rev Bras Psiquiatr (2004) 26:189-201. doi:10.1590/S1516-44462004000300009.
12. Carroll BJ, Cassidy F, Naftolowitz D, Tatham NE, Wilson WH, Iranmanesh A, et al. Pathophysiology of hypercortisolism in depression. Acta Psychiatr Scand (2007) 115:90-103. doi:10.1111/j.1600-0447.2007.00967.x.
13. Mello AF, Juruena MF, Pariante CM, Tyrka AR, Price LH, Carpenter LL, et al. Depression and stress: is there an endophenotype? Rev Bras Psiquiatr (2007) 29:S13-8. doi:10.1590/S1516-44462007000500004.
14. Shea A, Walsh C, Macmillan H, Steiner M. Child maltreatment and HPA axis dysregulation: relationship to major depressive disorder and post traumatic stress disorder in females. Psychoneuroendocrinology (2005) 30:162-78. doi:10.1016/j.psyneuen.2004.07.001.
15. Baes CVW, Tofoli SMC, Martins CMS, Juruena MF. Assessment of the hypothalamic-pituitary-adrenal axis activity: glucocorticoid receptor and mineralocorticoid receptor function in depression with early life stress-a systematic review. Acta Neuropsychiatr (2012) 24:4-15. doi:10.1111/j.1601-5215.2011.00610.x.
16. Pruessner JC, Wolf OT, Hellhammer DH, Buske-Kirschbaum A, von Auer K, Jobst S, et al. Free cortisol levels after awakening: a reliable biological marker for the assessment of adrenocortical activity. Life Sci (1997) 61:2539-49. doi:10.1016/S0024-3205(97)01008-4.
17. Clow A, Thorn L, Evans P, Hucklebridge F. The awakening cortisol response: methodological issues and significance. Stress (2004) 7:29-37. doi:10.1080/10253890410001667205.
18. Clow A, Hucklebridge F, Stalder T, Evans P, Thorn L. The cortisol awakening response: more than a measure of HPA axis function. Neurosci Biobehav Rev (2010) 35:97-103. doi:10.1016/j.neubiorev.2009.12.011.
19. Wilhelm I, Born J, Kudielka BM, Schlotz W, Wust S. Is the cortisol awakening rise a response to awakening? Psychoneuroendocrinology (2007) 32:358-66. doi:10.1016/j.psyneuen.2007.01.008.
20. Wust S, Wolf J, Hellhammer DH, Federenko I, Schommer N, Kirschbaum C. The cortisol awakening response-normal values and confounds. Noise Health (2000) 2:79-88. Available from: http://www.noiseandhealth.org/text.asp?2000/2/7/79/31739.
21. Bhagwagar Z, Hafizi S, Cowen PJ. Increase in concentration of waking salivary cortisol in recovered patients with depression. Am J Psychiatry (2003) 160:1890-1. doi:10.1176/appi.ajp.160.10.1890.
22. Stetler C, Miller GE. Blunted cortisol response to awakening in mild to moderate depression: regulatory influences of sleep patterns and social contacts. J Abnorm Psychol (2005) 114:697-705. doi:10.1037/0021-843X.114.4.697.
23. Fries E, Dettenborn L, Kirschbaum C. The cortisol awakening response (CAR): facts and future directions. Int J Psychophysiol (2009) 72:67-73. doi:10.1016/j.ijpsycho.2008.03.014.
24. Vreeburg SA, Hoogendijk WJ, van Pelt J, DeRijk RH, Verhagen JCM, van Dyck R, et al. Major depressive disorder and hypothalamic-pituitary-adrenal axis activity: results from a large cohort study. Arch Gen Psychiatry (2009) 66:617-26. doi:10.1001/archgenpsychiatry.2009.50.
25. Adam EK, Doane LD, Zinbarg RE, Mineka S, Craske MG, Griffith JW. Prospective prediction of major depressive disorder from cortisol awakening responses in adolescence. Psychoneuroendocrinology (2010) 35:921-31. doi:10.1016/j.psyneuen.2009.12.007.
26. Vrshek-Schallhorn S, Doane LD, Mineka S, Zinbarg RE, Craske MG, Adam EK. The cortisol awakening response predicts major depression: predictive stability over a 4-year follow-up and effect of depression history. Psychol Med (2013) 43:483-93. doi:10.1017/S0033291712001213.
27. Pariante CM, Miller AH. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry (2001) 49:391-404. doi:10.1016/S0006-3223(00)01088-X.
28. Spencer RL, Young EA, Choo PH, McEwen BS. Adrenal steroid type I and type II receptor binding: estimates of in vivo receptor number, occupancy, and activation with varying level of steroid. Brain Res (1990) 514:37-48. doi:10.1016/0006-8993(90)90433-C.
29. de Kloet ER, Vreugdenhil E, Oitzl MS, Joels M. Brain corticosteroid receptor balance in health and disease. Endocr Rev (1998) 19:269-301. doi:10.1210/er.19.3.269.
30. Grossmann C, Scholz T, Rochel M, Bumke-Vogt C, Oelkers W, Pfeiffer AFH, et al. Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV-1 cells: a comparison of their glucocorticoid and mineralocorticoid properties. Eur J Endocrinol (2004) 151:397-406. doi:10.1530/eje.0.1510397.
31. de Kloet ER, Joels M, Holsboer F. Stress and the brain: from adaptation to disease. Nat Rev Neurosci (2005) 6:463-75. doi:10.1038/nrn1683.
32. Reul JM, Gesing A, Droste S, Stec IS, Weber A, Bachmann C, et al. The brain mineralocorticoid receptor: greedy for ligand, mysterious in function. Eur J Pharmacol (2000) 405:235-49. doi:10.1016/S0014-2999(00)00677-4.
33. Pariante CM, Papadopoulos AS, Poon L, Checkley SA, English J, Kerwin RW, et al. A novel prednisolone suppression test for the hypothalamic-pituitary-adrenal axis. Biol Psychiatry (2002) 51:922-30. doi:10.1016/S0006-3223(01)01314-2.
34. Juruena MF, Cleare AJ, Papadopoulos AS, Poon L, Lightman S, Pariante CM. Different responses to dexamethasone and prednisolone in the same depressed patients. Psychopharmacology (2006) 189:225-35. doi:10.1007/s00213-006-0555-4.
35. Pariante CM, Lightman SL. The HPA axis in major depression: classical theories and new developments. Trends Neurosci (2008) 31:464-8. doi:10.1016/j.tins.2008.06.006.
36. Juruena MF, Pariante CM, Cleare AJ, Papadopoulos AS, Poon L, Lightman S. The prednisolone suppression test in depression: dose-response and changes with antidepressant treatment. Psychoneuroendocrinology (2010) 35:1486-91. doi:10.1016/j.psyneuen.2010.04.016.
37. Carroll BJ, Curtis GC, Mendels J. Neuroendocrine regulation in depression. II. Discrimination of depressed from nondepressed patients. Arch Gen Psychiatry (1976) 33:1051-8. doi:10.1001/archpsyc.1976.01770090041003.
38. Carroll BJ, Feinberg M, Greden JF, Tarika J, Albala AA, Haskett RF, et al. A specific laboratory test for the diagnosis of melancholia. Standardization, validation, and clinical utility. Arch Gen Psychiatry (1981) 38:15-22. doi:10.1001/archpsyc.1981.01780260017001.
39. Ribeiro SC, Tandon R, Grunhaus L, Greden JF. The DST as a predictor of outcome in depression: a meta-analysis. Am J Psychiatry (1993) 150:1618-29.
40. Juruena MF, Pariante CM, Papadopoulos A, Cleare AJ. The development and application of the prednisolone suppression test in psychiatry: a novel tool for assessing glucocorticoid and mineralocorticoid receptor function. Mind Brain (2010) 1:115-22. Available from: http://scholar.google.com.br/scholar?oi=bibs&hl=pt-BR&cluster=12028518518942534865.
41. Carroll BJ. The dexamethasone suppression test for melancholia. Br J Psychiatry (1982) 140:292-304. doi:10.1192/bjp.140.3.292.
42. Galard R, Catalán R, Castellanos JM, Gallart JM. Plasma corticotrophin releasing factor in depressed patients before and after the dexamethasone suppression test. Biol Psychiatry (2002) 51:463-8. doi:10.1016/S0006-3223(01)01273-2.
43. Contreras F, Menchon JM, Urretavizcaya M, Navarro MA, Vallejo J, Parker G. Hormonal differences between psychotic and non-psychotic melancholic depression. J Affect Disord (2007) 100:65-73. doi:10.1016/j.jad.2006.09.021.
44. Arana G, Baldessarini R, Ornsteen M. The dexamethasone suppression test for diagnosis and prognosis in psychiatry. Arch Gen Psychiatry (1985) 42:1192-204. doi:10.1001/archpsyc.1985.01790350067012.
45. von Bardeleben U, Holsboer F. Effect of age on the cortisol response to human corticotropin-releasing hormone in depressed patients pretreated with dexamethasone. Biol Psychiatry (1991) 29:1042-50. doi:10.1016/0006-3223(91)90360-X.
46. Heuser I, Yassouridis A, Holsboer F. The combined dexamethasone/CRH test: a refined laboratory test for psychiatric disorders. J Psychiatr Res (1994) 28:341-56. doi:10.1016/0022-3956(94)90017-5.
47. Juruena MF, Pariante CM, Papadoulos AS, Poon L, Lightman S, Cleare AJ. Prednisolone suppression test in depression: prospective study of the role of HPA axis dysfunction in treatment resistance. Br J Psychiatry (2009) 194:342-9. doi:10.1192/bjp.bp.108.050278.
48. Buckley TM, Mullen BC, Schatzberg AF. The acute effects of a mineralocorticoid receptor (MR) agonist on nocturnal hypothalamic-adrenal-pituitary (HPA) axis activity in healthy controls. Psychoneuroendocrinology (2007) 32:859-64. doi:10.1016/j.psyneuen.2007.05.016.
49. Lembke A, Gomez R, Tenakoon L, Keller J, Cohen G, Williams GH, et al. The mineralocorticoid receptor agonist, fludrocortisone, differentially inhibits pituitary-adrenal activity in humans with psychotic major depression. Psychoneuroendocrinology (2013) 38:115-21. doi:10.1016/j.psyneuen.2012.05.006.
50. Otte C, Hinkelmann K, Moritz S, Yassouridis A, Jahn H, Wiedemann K, et al. Modulation of the mineralocorticoid receptor as add-on treatment in depression: a randomized, double-blind, placebo-controlled proof-of-concept study. J Psychiatr Res (2010) 44:339-46. doi:10.1016/j.jpsychires.2009.10.006.
51. Heuser I, Deuschle M, Weber B, Stalla GK, Holsboer F. Increased activity of the hypothalamus-pituitary-adrenal system after treatment with the mineralocorticoid receptor antagonist spironolactone. Psychoneuroendocrinology (2000) 25:513-8. doi:10.1016/S0306-4530(00)00006-8.
52. Young EA, Lopez JF, Murphy-Weinberg V, Watson SJ, Akil H. Mineralocorticoid receptor function in major depression. Arch Gen Psychiatry (2003) 60:24-8. doi:10.1001/archpsyc.60.1.24.
53. Bremner DJ. Long-term effects of childhood abuse on brain and neurobiology. Child Adolesc Psychiatr Clin N Am (2003) 12:271-292. doi:10.1016/S1056-4993(02)00098-6.
54. Bugental DB, Martorell GA, Barraza V. The hormonal costs of subtle forms of infant maltreatment. Horm Behav (2003) 43:237-44. doi:10.1016/S0018-506X(02)00008-9.
55. Newport DJ, Heim C, Bonsall R, Miller AH, Nemeroff CB. Pituitary-adrenal responses to standard and low-dose dexamethasone suppression tests in adult survivors of child abuse. Biol Psychiatry (2004) 55:10-20. doi:10.1016/S0006-3223(03)00692-9.
56. Bradley RG, Binder EB, Epstein MP, Tang Y, Nair HP, Liu W, et al. Influence of child abuse on adult depression: moderation by the corticotropin-releasing hormone receptor gene. Arch Gen Psychiatry (2008) 65:190-200. doi:10.1001/archgenpsychiatry.2007.26.
57. Tyrka AR, Wier L, Price LH, Ross N, Anderson GM, Wilkinson CW, et al. Childhood parental loss and adult hypothalamic-pituitary-adrenal function. Biol Psychiatry (2008) 63:1147-54. doi:10.1016/j.biopsych.2008.01.011.
58. Carpenter LL, Ross NS, Tyrka AR, Anderson GM, Kelly M, Price LH. Dex/CRH test cortisol response in outpatients with major depression and matched healthy controls. Psychoneuroendocrinology (2009) 34:1208-13. doi:10.1016/j.psyneuen.2009.03.009.
59. Klaassens ER, van Noorden MS, Giltay EJ, van Pelt J, van Veen T, Zitman FG. Effects of childhood trauma on HPA-axis reactivity in women free of lifetime psychopathology. Prog Neuropsychopharmacol Biol Psychiatry (2009) 33:889-94. doi:10.1016/j.pnpbp.2009.04.011.
60. Juruena MF, Pariante CM, Papadopoulos A, Poon L, Lightman S, Cleare AJ. The role of mineralocorticoid receptor function in treatment-resistant depression. J Psychopharmacol (2013) 27(12):1169-79. doi:10.1177/0269881113499205.
61. Jarcho MR, Slavich GM, Tylova-Stein H, Wolkowitz OM, Burke HM. Dysregulated diurnal cortisol pattern is associated with glucocorticoid resistance in women with major depressive disorder. Biol Psychol (2013) 93:150-8. doi:10.1016/j.biopsycho.2013.01.018.
62. APA. Diagnostic and Statistical Manual of Mental Disorders, DSM-IV. Washington, DC: American Psychiatric Association (1994).
63. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry (1960) 23:56-62. doi:10.1136/jnnp.23.1.56.
64. Bernstein DP, Fink L, Handelsman L, Foote J, Lovejoy M, Wenzel K, et al. Initial reliability and validity of a new retrospective measure of child abuse and neglect. Am J Psychiatry (1994) 151:1132-6.
65. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry (1998) 59:22-33.
66. Amorim P. Mini International Neuropsychiatric Interview (MINI): validation of a short structured diagnostic psychiatric interview. Rev Bras Psiquiatr (2000) 22:106-15. doi:10.1590/S1516-44462000000300003.
67. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry (2006) 163:1905-17. doi:10.1176/appi.ajp.163.11.1905.
68. Bernstein DP, Stein JA, Newcomb MD, Walker E, Pogge D, Ahluvalia T, et al. Development and validation of a brief screening version of the childhood trauma questionnaire. Child Abuse Negl (2003) 27:169-90. doi:10.1016/S0145-2134(02)00541-0.
69. Grassi-Oliveira R, Stein LM, Pezzi JC. Translation and content validation of the Childhood Trauma Questionnaire into Portuguese language. Rev Saude Publica (2006) 40:249-55. doi:10.1590/S0034-89102006000200010.
70. Santiago LB, Jorge SM, Moreira AC. Longitudinal evaluation of the development of salivary cortisol circadian rhythm in infancy. Clin Endocrinol (Oxf) (1996) 44:157-61. doi:10.1046/j.1365-2265.1996.645466.x.
71. Pruessner JC, Kirschbaum C, Meinlschmid G, Hellhammer DH. Two formulas for computation of the area under the curve represent measures of total hormone concentration versus time-dependent change. Psychoneuroendocrinology (2003) 28:916-31. doi:10.1016/S0306-4530(02)00108-7.
72. Yehuda R. Biology of posttraumatic stress disorder. J Clin Psychiatry (2001) 62:41-6. Available from: http://www.psychiatrist.com/private/supplenet/v62s17/v62s1708.pdf.
73. Gold PW, Chrousos GP. Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH/NE states. Mol Psychiatry (2002) 7:254-75. doi:10.1038/sj.mp.4001032.
74. Juruena MF, Cleare AJ. Overlap between atypical depression, seasonal affective disorder and chronic fatigue syndrome. Rev Bras Psiquiatr (2007) 29:19-26. doi:10.1590/S1516-44462007000500005.
75. Yehuda R, Seckl J. Minireview: stress-related psychiatric disorders with low cortisol levels: a metabolic hypothesis. Endocrinology (2011) 152:4496-503. doi:10.1210/en.2011-1218.
76. Stein MB, Yehuda R, Koverola C, Hanna C. Enhanced dexamethasone suppression of plasma cortisol in adult women traumatized by childhood sexual abuse. Biol Psychiatry (1997) 42:680-6. doi:10.1016/S0006-3223(96)00489-1.
77. Sullivan PF, Kessler RC, Kendler KS. Latent class analysis of lifetime depressive symptoms in the national comorbidity survey. Am J Psychiatry (1998) 155:1398-1406.
78. Matza LS, Revicki DA, Davidson JR, Stewart JW. Depression with atypical features in the National Comorbidity Survey: classification, description, and consequences. Arch Gen Psychiatry (2003) 60:817-26. doi:10.1001/archpsyc.60.8.817.
79. Coryell W. The facets of melancholia. Acta Psychiatr Scand (2007) 433:31-6. doi:10.1111/j.1600-0447.2007.00960.x.
80. Withers AC, Tarasoff JM, Stewart JW. Is depression with atypical features associated with trauma history? J Clin Psychiatry (2013) 74:500-6. doi:10.4088/JCP.12m07870.
81. Tsigos C, Chrousos GP. Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. J Psychosom Res (2002) 53:865-71. doi:10.1016/S0022-3999(02)00429-4.
82. Antonijevic IA. Depressive disorders-is it time to endorse different pathophysiologies? Psychoneuroendocrinol (2006) 31:1-15. doi:10.1016/j.psyneuen.2005.04.004.
83. Stetler C, Miller GE. Depression and hypothalamic-pituitary-adrenal activation: a quantitative summary of four decades of research. Psychosom Med (2011) 73:114-26. doi:10.1097/PSY.0b013e31820ad12b.
84. Paslakis G, Krumma B, Gilles M, Schweiger U, Heuser I, Inga R, et al. Discrimination between patients with melancholic depression and healthy controls: comparison between 24-h cortisol profiles, the DST and the Dex/CRH test. Psychoneuroendocrinology (2011) 36:691-8. doi:10.1016/j.psyneuen.2010.10.002.
85. O'Keane V, Frodl T, Dinan TG. A review of Atypical depression in relation to the course of depression and changes in HPA axis organization. Psychoneuroendocrinology (2012) 37:1589-99. doi:10.1016/j.psyneuen.2012.03.009.
86. Wang SS, Kamphuis W, Huitinga I, Zhou JN, Swaab DF. Gene expression analysis in the human hypothalamus in depression by laser microdissection and real-time PCR: the presence of multiple receptor imbalances. Mol Psychiatry (2008) 13:786-99. doi:10.1038/mp.2008.38.
87. Yau JL, Noble J, Hibberd C, Seckl JR. Short-term administration of fluoxetine and venlafaxine decreases corticosteroid receptor mRNA expression in the rat hippocampus. Neurosci Lett (2001) 306:161-4. doi:10.1016/S0304-3940(01)01890-0.
88. Juruena MF, Gama CS, Berk M, Belmonte-de-Abreu PS. Improved stress response in bipolar affective disorder with adjunctive spironolactone (mineralocorticoid receptor antagonist): case series. J Psychopharmacol (2009) 23:985-7. doi:10.1177/0269881108092121.
89. Lopez JF, Chalmers DT, Little KY, Watson SJ. A.E. Bennett Research Award. Regulation of serotonin1A, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: implications for the neurobiology of depression. Biol Psychiatry (1998) 43:547-73. doi:10.1016/S0006-3223(97)00484-8.
90. Pfennig A, Kunzel HE, Kern N, Ising M, Majer M, Fuchs B, et al. Hypothalamus-pituitary-adrenal system regulation and suicidal behavior in depression. Biol Psychiatry (2005) 57:336-42. doi:10.1016/j.biopsych.2004.11.017.
91. Kunugi H, Ida I, Owashi T, Kimura M, Inoue Y, Nakagawa S, et al. Assessment of the dexamethasone/CRH test as a state-dependent marker for hypothalamic-pituitary-adrenal (HPA) axis abnormalities in major depressive episode: a multicenter study. Neuropsychopharmacology (2006) 31:212-20. doi:10.1038/sj.npp.1300868.
92. Gervasoni N, Bertschy G, Osiek C, Perret G, Denis R, Golaz J, et al. Cortisol responses to combined dexamethasone/CRH test in outpatients with a major depressive episode. J Psychiatr Res (2004) 38:553-7. doi:10.1016/j.jpsychires.2004.04.008.
93. Owashi T, Otsubo T, Oshima A, Nakagome K, Higuchi T, Kamijima K. Longitudinal neuroendocrine changes assessed by dexamethasone/CRH and growth hormone releasing hormone tests in psychotic depression. Psychoneuroendocrinology (2008) 33:152-61. doi:10.1016/j.psyneuen.2007.10.011.
94. Glover V, O'Connor TG. Effects of antenatal stress and anxiety: implications for development and psychiatry. Br J Psychiatry (2002) 180:389-91. doi:10.1192/bjp.180.5.389.
95. Carpenter LL, Tyrka AR, Ross NS, Khoury L, Anderson GM, Price LH. Effect of childhood emotional abuse and age on cortisol responsivity in adulthood. Biol Psychiatry (2009) 66:69-75. doi:10.1016/j.biopsych.2009.02.030.
96. Weaver IC, Cervoni N, Champagne FA, D'Alessio AC, Sharma S, Seckl JR, et al. Epigenetic programming by maternal behavior. Nat Neurosci (2004) 7:847-854. doi:10.1038/nn1276.
97. Kunzel HE, Binder EB, Nickel T, Ising M, Fuchs B, Majer M, et al. Pharmacological and nonpharmacological factors influencing hypothalamic-pituitary-adrenocortical axis reactivity in acutely depressed psychiatric inpatients, measured by the Dex-CRH test. Neuropsychopharmacology (2003) 28:2169-78. doi:10.1038/sj.npp.1300280.
98. Chrousos GP, Gold PW. The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis. JAMA (1992) 267:1244-52. Erratum in: JAMA (1992) 268:200. doi:10.1001/jama.1992.03480090092034.